Humanwell Healthcare (Group)Ltd マネジメント

マネジメント基準チェック /24

Humanwell Healthcare (Group)Ltdの CEO はXiafei Dengで、 Jun2020年に任命され、の在任期間は 4.42年です。は、会社の株式の0.098%を直接所有しており、その価値はCN¥ 35.44M 。経営陣と取締役会の平均在任期間はそれぞれ4.6年と9年です。

主要情報

Xiafei Deng

最高経営責任者

CN¥7.2m

報酬総額

CEO給与比率	n/a
CEO在任期間	4.4yrs
CEOの所有権	0.1%
経営陣の平均在職期間	4.6yrs
取締役会の平均在任期間	9yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Xiafei Deng (60 yo)

4.4yrs

在職期間

CN¥7,185,300

報酬

Mr. Xiafei Deng serves as President at Humanwell Healthcare (Group) Co.,Ltd. since June 2020. He serves as Director of Wuhan Humanwell Healthcare (Group) Co.,Ltd.and served as its Vice President until Jun...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Xiafei Deng	President & Director	4.4yrs	CN¥7.19m	0.098% CN¥ 35.4m
Yajun Wu	CFO & VP	20.7yrs	CN¥2.08m	0.059% CN¥ 21.6m
Qianlun Li	VP & Secretary	11.5yrs	CN¥1.97m	0.019% CN¥ 6.8m
Wentao Du	Vice President	21.1yrs	CN¥4.07m	0.056% CN¥ 20.2m
Lie Li	Vice President	4.6yrs	CN¥3.70m	0.032% CN¥ 11.6m
Hongjie Zhang	Vice President	no data	CN¥4.97m	0.028% CN¥ 10.1m
Qiang Yin	Vice President	4.6yrs	CN¥1.97m	0.028% CN¥ 10.1m
Qun Yu	Vice President	4.1yrs	CN¥3.69m	0.028% CN¥ 10.1m

4.6yrs

平均在職期間

54.5yo

平均年齢

経験豊富な経営陣: 600079の経営陣は経験豊富であると考えられます ( 4.6年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Xiafei Deng	President & Director	25.8yrs	CN¥7.19m	0.098% CN¥ 35.4m
Min Qi	Supervisor	10.5yrs	データなし	データなし
Rui Zhou	Independent Director	3.5yrs	CN¥100.00k	データなし
Lin Qing Liu	Independent director	4.5yrs	CN¥100.00k	データなし
Xiao Dong Zhang	Director	27.8yrs	CN¥1.81m	0.029% CN¥ 10.4m
Xuehai Wang	Director	21.5yrs	CN¥618.50k	0.22% CN¥ 81.5m
Jie Li	Chairman of the Board	21.5yrs	CN¥5.67m	5.39% CN¥ 2.0b
Yue Xin Du	Chairman of the Supervisory Board	19.7yrs	CN¥66.00k	データなし
Hansheng Zhou	Director	7.6yrs	CN¥1.81m	データなし
Chenggang Zheng	Supervisor	4.5yrs	データなし	データなし
Kong Na	Representative Member of the Supervisory Board	4.5yrs	データなし	データなし
Xia Yuan	Employee Representative Member of the Supervisory Board	4.5yrs	データなし	データなし

9.0yrs

平均在職期間

55yo

平均年齢

経験豊富なボード: 600079の取締役会は経験豊富であると考えられます ( 9年の平均在任期間)。

Humanwell Healthcare (Group)Ltd マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Humanwell Healthcare (Group) Co.,Ltd., Annual General Meeting, Apr 25, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.30 (vs CN¥0.27 in 3Q 2023)

Upcoming dividend of CN¥0.15 per share

Humanwell Healthcare (Group) Co.,Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Investor sentiment improves as stock rises 21%

Investor sentiment deteriorates as stock falls 16%

Second quarter 2024 earnings released: EPS: CN¥0.38 (vs CN¥0.41 in 2Q 2023)

Humanwell Healthcare (Group) Co.,Ltd. to Report First Half, 2024 Results on Aug 15, 2024

Dividend of CN¥0.46 announced

First quarter 2024 earnings released: EPS: CN¥0.30 (vs CN¥0.41 in 1Q 2023)

Full year 2023 earnings released: EPS: CN¥1.32 (vs CN¥1.54 in FY 2022)

Humanwell Healthcare (Group) Co.,Ltd., Annual General Meeting, Apr 25, 2024

Investor sentiment improves as stock rises 17%

Humanwell Healthcare (Group) Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 29, 2024

Third quarter 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.42 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.41 (vs CN¥0.35 in 2Q 2022)

Full year 2022 earnings released: EPS: CN¥1.54 (vs CN¥0.83 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.42 (vs CN¥0.27 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.41 (vs CN¥0.23 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: CN¥0.58 (vs CN¥0.19 in 1Q 2021)

Less than half of directors are independent

Novo Holdings A/S agreed to acquire The Ritedose Corporation from AGIC Capital, Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079) and others.

Third quarter 2021 earnings released: EPS CN¥0.27 (vs CN¥0.16 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.19 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.10 in 1Q 2020)

Investor sentiment improved over the past week

New 90-day low: CN¥26.05

Investor sentiment improved over the past week

New 90-day low: CN¥27.26

New 90-day low: CN¥30.20

Humanwell Healthcare (Group) Co.,Ltd. to Report Q3, 2020 Results on Oct 26, 2020

New 90-day low: CN¥30.82

Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079) entered into a preliminary letter of intent to acquire an additional 13% stake in YiChang Humanwell Pharmaceutical Co., Ltd from Li Jie, Chen Xiaoqing, and Xu Huabin.

New 90-day high - CN¥38.00

Chongqing Pharmaceutical (Group) Co., Ltd. signed the Sichuan Humanwell Pharmaceutical Co., Ltd. Equity Transfer Contract to acquire 70% stake in Sichuan Humanwell Pharmaceutical Co., Ltd from Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079) for approximately CNY 360 million.

New 90-day high - CN¥36.59

Humanwell Healthcare (Group) Co.,Ltd. to Report First Half, 2020 Results on Aug 22, 2020

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24